曲妥珠单抗-美坦新偶联物
|
|
- CAS号:
- 1018448-65-1
- 英文名:
- Trastuzumab emtansine
- 英文别名:
- T-DM1;Kadcyla;PRO132365;trastuzumab-DM1;trastuzumab-MCC-DM1;trastuzumab emtansine;Ado-trastuzumab emtansine;Ado-trastuzuMab-eMtansine cas nr;Ado-trastuzumab Emtansine (TDM-1);trastuzumab-MCC-DM1 antibody-drug conjugate
- 中文名:
- 曲妥珠单抗-美坦新偶联物
- 中文别名:
- 曲妥珠单抗-美坦新偶联物;曲妥珠单抗-EMTANSINE偶联物;曲妥珠单抗-美坦新偶联物 (TDM-1)
- CBNumber:
- CB12672561
- 分子式:
- 分子量:
- 0
- MOL File:
- Mol file
|
|
|
曲妥珠单抗-美坦新偶联物化学性质
-
储存条件:
-
Store at -20°C
-
|
-
形态:
-
Solid
-
|
-
颜色:
-
White to off-white
-
|
曲妥珠单抗-美坦新偶联物性质、用途与生产工艺
Trastuzumab emtansine (Ado-Trastuzumab emtansine) 是一种抗体偶联药物 (ADC),其结合了 HER2 靶向的曲妥珠单抗的抗肿瘤特性以及微管抑制剂 DM1 的细胞毒活性。Trastuzumab emtansine 可用于晚期乳腺癌的研究。
Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells.
Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice.
Animal Model:
|
CB-17/SCID mice (6 weeks) were injected with OVA10 cells
|
Dosage:
|
15 mg/kg
|
Administration:
|
I.v. three to five times weekly for 3 weeks
|
Result:
|
Showed remarkable inhibition of tumor growth in mice and was well tolerated.
|
曲妥珠单抗-美坦新偶联物
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/08/19 | HY-P9921 | 曲妥珠单抗-美坦新偶联物 Trastuzumab emtansine | 1018448-65-1 | 1mg | 4800元 |
2023/10/26 | HY-P9921 | 曲妥珠单抗-美坦新偶联物 Trastuzumab emtansine | 1018448-65-1 | 5mg | 16000元 |
1018448-65-1, 曲妥珠单抗-美坦新偶联物 相关搜索:
- 化学试剂-精细化工
- 高纯试剂
- 化学试剂
- 医药原料
- 曲妥珠单抗-美坦新偶联物
- 曲妥珠单抗-EMTANSINE偶联物
- 曲妥珠单抗-美坦新偶联物 (TDM-1)
- 1018448-65-1
- trastuzumab-MCC-DM1 antibody-drug conjugate
- trastuzumab-MCC-DM1
- trastuzumab-DM1
- T-DM1
- PRO132365
- Kadcyla
- Ado-trastuzumab Emtansine (TDM-1)
- Ado-trastuzumab emtansine
- trastuzumab emtansine
- Ado-trastuzuMab-eMtansine cas nr